Working… Menu
Trial record 4 of 232 for:    CALCITONIN SALMON

A Study of Oral Calcitonin Given at Night to Healthy Postmenopausal Women

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00803686
Recruitment Status : Completed
First Posted : December 5, 2008
Results First Posted : June 9, 2014
Last Update Posted : June 9, 2014
Information provided by (Responsible Party):
Tarsa Therapeutics, Inc.

Brief Summary:
This study is being conducted to assess the plasma CTx-1 concentrations when dosing is at night and to compare these results with those obtained with a placebo control and with commercially available nasal calcitonin.

Condition or disease Intervention/treatment Phase
Phase 1 Pharmacodynamic Study Drug: Oral rsCT tablet Drug: Oral Placebo Tablet Drug: Fortical (rsCT) nasal spray Phase 2

Detailed Description:
Timing of the dose of recombinant salmon calcitonin (rsCT) is important in effecting reduction of osteoclast activity. It is theorized that a dose administered before bedtime will be more effective than a dose administered in the morning. See protocol summary for information.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomized, Open-Label, Placebo-Controlled, Two-Period Crossover Study of the Effect on CTx-1 Concentrations of a Single 200 μg Recombinant Salmon Calcitonin (rsCT) Dose Given at Night to Normal, Healthy, Postmenopausal Women
Study Start Date : December 2008
Actual Primary Completion Date : January 2009
Actual Study Completion Date : January 2009

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Part 1 Double Blind Oral rsCT Tablet
Intervention: Oral rsCT tablet given once 4 hours after evening meal.
Drug: Oral rsCT tablet
On Study Day 1, subjects will be given their assigned treatment, based on one of two randomly ordered treatment sequences, at 10 PM (22:00). On Visit 3, subjects will return for administration of the second treatment with a minimum of 7 days washout interval between study drug administrations. On Visit 4, subjects will return for administration of third treatment of rsCT, either oral rsCT tablets or Fortical (rsCT) nasal spray. Interventions are described in Intervention Name, Other Names and in Intervention Description.
Other Name: rsCT

Placebo Comparator: Part 1, Double-blind Oral Placebo Tablet
Intervention: Oral placebo tablet matching the oral rsCT tablet, given once 4 hours after evening meal
Drug: Oral Placebo Tablet
Part 1, Double blind oral placebo tablet given once 4 hours after evening meal.
Other Name: Placebo

Experimental: Part 2 Open label, Oral rsCT tablet
Intervention: Oral rsCT tablet given once 2 hours after evening meal.
Drug: Oral rsCT tablet
Part 2, Open-label, oral rsCT tablet given once 2 hours after the evening meal.

Active Comparator: Part 2, Open Label Fortical Nasal Spray
Intervention: Part 2 Open label. Fortical (rsCT) nasal spray given once 2 hours after evening meal
Drug: Fortical (rsCT) nasal spray
Intervention: Open label, Fortical nasal spray given once 2 hours after the evening meal.
Other Name: Fortical nasal spray

Primary Outcome Measures :
  1. Pharmacodynamic Effect of Oral Calcitonin [ Time Frame: 12 hr ]
    C-terminal telopeptide of Collagen Type I (CTx-1) is an established plasma biomarker employed as an index of bone-resorption activity in response to interventions such as an anti-resorptive agent such as calcitonin. Here the calcitonin-salmon is rsCT, (recombinant) both oral and intranasal. These CTx-1 plasma concentrations were collected over 12 hours post-dosing where each subject served as her own control, as all received placebo in this crossover study, to account for the known diurnal variation of plasma CTx-1. For each time point, the ratio of the calcitonin response over the placebo response for that subject was derived from the plasma levels of CTx-1 and reported as a % of the placebo response (% Placebo or %P). These values were used to determine the primary pharmacodynamic parameter of Rmin, the minimum value seen following each active dose. The same %P values were used to derive the secondary pharmacodynamic parameters described in Secondary outc

Secondary Outcome Measures :
  1. Derived Pharmacodynamic Parameters Further Characterizing the Effects of Oral or Intranasal Calcitonin on Plasma CTx-1, Given at Night to Post-menopausal Women [ Time Frame: 12 hours ]
    See Primary Outcome description. These CTx-1 plasma concentrations were collected over 12 hours, the values seen following active were compared with the time-matched individual values following placebo and used to derive the pharmacodynamic parameters. The primary was Rmin, seen above, and the Secondary ones were the time to that Rmin (Tmin) and the total time from the beginning of the inhibition to the end of the effect or the end of the study period (Tinhibition).

  2. AUCInhibition=Hours*%P [ Time Frame: 12 Hours ]
    The AUCinhibition, (Area Under the Inhibition Curve) in hours*%inhibition vs placebo under the baseline line over the curve.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   45 Years to 70 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria

  • Postmenopausal female, in good health (at least five years since last menses).
  • Age greater than or equal to 45 years old and less than or equal to 70 years old
  • Weight ± 20% of the Metropolitan Life weight table.
  • Plasma CTx-1 greater than or equal to 0.25 ng/ml.
  • Total calcium, phosphorus, and magnesium within normal range.
  • Willing and able to comply with all study requirements.
  • Willing and able to sign written informed consent.
  • Negative urine pregnancy test at screening.
  • Negative Screen for Hepatitis B and C, HIV and drugs of abuse.

Exclusion Criteria:

  • History of parathyroid, thyroid, pituitary or adrenal diseases.
  • History of musculoskeletal disease.
  • History of gastro-esophageal reflux disease (GERD) or other significant gastrointestinal disorders.
  • History of cancer within 5 years of enrollment other than basal cell carcinoma.
  • History of regular use of a Non-Steroidal Anti-inflammatory Drug (NSAID).
  • History of surgery within 60 days of enrollment.
  • History of hypersensitivity or allergies (other than seasonal allergies) within -years of enrollment including known sensitivity to the active ingredients or the excipients in the study medications.
  • Use of concomitant medications other than acetaminophen within 7 days of enrollment or anticipated need to use such concomitant medications during the study.
  • Use of bisphosphonates within 6 months, SERMS, estrogen or estrogen-like drugs 2 months, or calcitonin 1 month.
  • Presence of any clinically significant illness.
  • Unwilling or unable to comply with all study requirements.
  • Unwilling or unable to sign written, informed consent.
  • History of drug or alcohol abuse.
  • Participation in any clinical study of an investigational drug within 60 days of enrollment.
  • Plasma CTx-1 less than 0.25 ng/mL.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00803686

Layout table for location information
United States, Missouri
Bio-Kinetic Clinical Applications, Inc.
Springfield, Missouri, United States, 65802
Sponsors and Collaborators
Tarsa Therapeutics, Inc.
Layout table for investigator information
Principal Investigator: Thomas Legg, D.O. Bio-Kinetic Clinical Applications, Inc.

Layout table for additonal information
Responsible Party: Tarsa Therapeutics, Inc. Identifier: NCT00803686     History of Changes
Other Study ID Numbers: UGL-OR0803
Bio-Kinetic No.: 13808 ( Other Identifier: Unigene Laboratories 0803 )
First Posted: December 5, 2008    Key Record Dates
Results First Posted: June 9, 2014
Last Update Posted: June 9, 2014
Last Verified: June 2014
Additional relevant MeSH terms:
Layout table for MeSH terms
Salmon calcitonin
Calcitonin Gene-Related Peptide
Calcium-Regulating Hormones and Agents
Physiological Effects of Drugs
Bone Density Conservation Agents
Vasodilator Agents